BUZZ-Aclaris rises as inflammation drug shows promise in early trial

Reuters01-06
BUZZ-Aclaris rises as inflammation drug shows promise in early trial 

** Shares of drug developer Aclaris Therapeutics ACRS.O rise 2.3% to $2.71 premarket

** Co says its experimental drug ATI-052 showed promising safety and effectiveness in an early-stage clinical trial

** ATI-052 aims to treat atopic dermatitis, or eczema, and asthma by blocking inflammation signals - ACRS

** Co says drug was well tolerated, with mild side effects such as temporary redness at injection site

** ATI-052 stayed in body for 26 days, and may allow dosing once every three months - ACRS

** Co plans proof-of-concept trials early this year; larger mid-stage trial in second half of 2026

** As of last close, ACRS up ~44% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment